Pfizer agrees to license 30 products to Russian pharma company
US drugs company Pfizer has entered into a manufacturing and licensing agreement with Russian pharmaceutical company NovaMedica.
Pfizer has proposed to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region.
The technology for production of more than 30 medicinal products from Pfizer’s portfolio will also be licensed to the Russian company.
In a press release, Pfizer and NovaMedica announced that the design, development and construction of the manufacturing plant are scheduled to begin in 2016, with the start of medicine production planned for 2020.
Petra Weil, regional president of Europe from Pfizer, said: “We contribute broadly to the modernisation of the Russian pharmaceutical industry, education in medicine and high-quality manufacturing and bringing innovation in the field of medicine.”
Brian Dovey, member of the board of directors of NovaMedica, said: “The strategic partnership with Pfizer provides a major boost toward NovaMedica’s goal of becoming a world-class leader in the fast-growing Russian pharmaceutical market.”
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk